Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


UK MHRA asks physicians to prescribe licensed melatonin products

This article was originally published in Scrip

Executive Summary

The UK MHRAis urging doctors and pharmacists to prescribe and supply only licensed melatonin, now that Lundbeck's modified-release product Circadin 2mg tablets are available in the UK. Before June, melatonin was only available in the UK as an unlicensed product. Many of these were non-pharmaceutical grade (non-GMP) products imported from the US, where they are classed as supplements, the MHRA points out. However, the agency recognises that there may be individuals for whom the licensed product does not meet their clinical needs, such as when alternative dosage forms are required, and licensed melatonin products can still be imported when prescribers give written details of the special clinical need to the importer, which submits this to the MRHA. Melatonin products have previously been the largest category of unlicensed products imported into the UK; the agency received 1,053 notifications of imports of these products in the six months to June.

You may also be interested in...

Botox shows hope in chronic migraine

Cerimon receives positive Phase II data on diclofenac patch

Cerimon Pharmaceuticals' once-daily topical-patch formulation of the NSAID diclofenac gave significantly better average pain relief than placebo in ankle-sprain patients who carried out their daily activities in a Phase II trial, at the third day in the study.

Lilly's Alimta among SMC's September recommendations

Following a second resubmission, the Scottish Medicines Consortiumhas accepted Lilly's Alimta (pemetrexed) for restricted use within the Scottish NHS as a monotherapy for the second-line treatment of locally advanced or metastatic non-small cell lung cancer.


Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts